-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
-
Summary
-
Kairos Pharma, LTD. quarterly Deferred Tax Assets, Valuation Allowance history and change rate from Q4 2023 to Q4 2024.
- Kairos Pharma, LTD. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $841,000, a 46.8% decline year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)